Background: Androgenetic alopecia (AGA) is a hereditary androgen-dependent disorder, characterized by a progressive decline in hair fibre production by scalp hair follicles and their eventual miniaturization. Metabolic syndrome is a cluster of inter-related risk factors that increase the risk of coronary artery disease. Despite the high burden of Androgenetic Alopecia and Metabolic Syndrome in India, specific data on the participants are relatively sparse.   Methods: A total of 126 patients of androgenetic alopecia (age range 18-55 years; mean age 30.83±10.37 years; 83.3% males) falling in sampling frame were enrolled in the study and were assessed clinically, anthropometrically and biochemically. Metabolic syndrome was diagnosed using Joint interim statement of International Diabetes Federation, National Heart, Lung and Blood Institute, American Heart Association, World Health Federation, International Atherosclerosis Society, and International Association of the Study of Obesity criteria.   Results: Prevalence of Metabolic Syndrome (MetS) was 29.4% in 126 cases of Androgenetic Alopecia. The P Value was <0.001 for obesity (52.4%), hypertension (35.7%), low HDL cholesterol (21.4%), hypertriglyceridemia (13.5%) and high fasting glucose (12.7%) respectively. Patients with higher severity grade of AGA had significantly higher prevalence of MetS and its components.   Conclusions: Metabolic Syndrome showed a positive relation with Androgenetic Alopecia. Early screening for Metabolic Syndrome is beneficial in patients with androgenic alopecia to prevent them from developing coronary artery disease.

<p class="abstract">Median canaliform dystrophy (MCD); first described by Heller in 1928 is characterized by a midline or paramedian split in the nail plate. Mostly idiopathic, some identifiable causes include habitual picking of the nails, oral isotretinoin use and positive family history. The familial occurrence of MCD has rarely been described. Till date, no therapy has proven to be consistently successful in effectively managing the condition. Commonly utilized treatments have been intralesional triamcinolone acetonide injections into the dystrophic nail, topical 0.1% tacrolimus ointment and topical tazarotene 0.05% ointment. Despite available treatment options, the condition has a tendency to recur. Here; we report a case of a 14‑year‑old male presenting with familial MCD affecting multiple finger and toe nails.</p>